LIVERMORE: LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis

Sponsor

Azienda Ospedaliero-Universitaria di Modena (Other)

Overall Status

Recruiting

CT.gov ID

NCT05186116

Collaborator

(none)

Enrollment

Location

Arm

120

Anticipated Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT for unresectable CRLM.

Secondary outcomes are graft survival and donor outcomes in terms of safety and quality of life.

Donor selection is performed according to the currently used Institutional and National standards and protocols.

Condition or Disease	Intervention/Treatment	Phase
Colon Adenocarcinoma Liver Metastasis Colon Cancer	Procedure: Living donor liver transplant	N/A

Detailed Description

Liver Transplant (LT) is a feasible, safe and effective curative strategy for patients with unresectable colorectal liver metastases (CRLM), and several trials are currently active and in a recruitment phase to study its impact with both conventional donors and living donors (LDLT).

As a matter of fact, in this setting living donors represent a helpful resource, thanks to the opportunity to schedule the LT at the timeliest conditions in terms of oncological response and patient's performance status. LDLT is a well-established procedure that is already offered to patients listed for LT at our Institution.

Crucial requirement for study eligibility is the assessment of non-resectability of the presented liver metastases from colorectal cancer (CRC).

Criteria for non-resectability of the liver-only CRC metastases eligible for the study should be assessed at the patient study entry, by the surgeon in charge together with the multidisciplinary team.

Patients fulfilling the inclusion criteria of the study will undergo clinical, translational and regulatory steps. Briefly, the main procedures and requirements of the study can be summarized as follows:

Pre-transplant screening and waiting phase:

Screening of patients with liver-limited CRC metastases potentially eligible to the study will be registered. The screening for general eligibility to liver transplantation will be conducted according to the existing Institutional protocol (called in Italian "PDTA", "Percorso Diagnostico Terapeutico Assistenziale").

During screening or waiting time periods, patients will continue planned chemotherapy treatment and will undergo blood tests (including CEA and Ca19.9), thoraco-abdominal CT scan and positron emission tomography (PET) scan (if needed) every 8 weeks.

Donors' screening:

Screening of donors will be held according to the existing Institutional protocol for LDLT

Informed consent:

Consent to the study will be signed after completion of the pre-LT screening, that is once co-morbidities and transplant eligibility will be ascertained on top of cancer conditions. In addition, patients will have to sign additional written informed consent prior to any study procedure.

Post-transplant follow-up:

Following LDLT, standard institutional follow-up procedures will be performed and registered. Patient/graft condition and tumor status should be re-assessed at least every 4 months for the first 3 years, every 6 months for the rest of follow-up.

Following donation standard institutional follow up will be performed on donors and registered.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

25 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Living Donor Liver Transplantation (LDLT) in Non Resectable Colo-rectal Cancer Liver Metastasis. The LIVERMORE Trial (LIVing Donor livEr tRansplant Modena cOloRectal mEtastasis) [Original Title in Italian: "Trapianto di Fegato da Donatore Vivente Per Metastasi Epatiche Non Resecabili da Adenocarcinoma Del Colon"]

Actual Study Start Date :

Jan 1, 2022

Anticipated Primary Completion Date :

Jan 1, 2027

Anticipated Study Completion Date :

Jan 1, 2032

Arms and Interventions

Arm	Intervention/Treatment
Experimental: LDLT recipients Patients that undergo LDLT for CRLM in the study period	Procedure: Living donor liver transplant Transplantation of part of the liver from a living donor

Arm

Intervention/Treatment

Experimental: LDLT recipients

Patients that undergo LDLT for CRLM in the study period

Procedure: Living donor liver transplant

Transplantation of part of the liver from a living donor

Outcome Measures

Primary Outcome Measures

Overall survival [5 years]
Overall survival of patients treated with LDLT for unresectable CRLM compared to our historical cohort of potentially transplantable patients that underwent chemotherapy only
Disease free survival [5 years]
Disease-free survival of patients treated with LDLT for unresectable CRLM compared to our historical cohort of potentially transplantable patients that underwent chemotherapy only

Secondary Outcome Measures

Graft survival [5 years]
Incidence of retransplant in the LDLT group
Donor quality of life [5 years]
Measure of Health-related quality of life (HRQOL) of donors using the a Short Form Health Survey 36 (SF-36). SF-36 is a multiplanar scale with scores ranging from 0 to 100 where zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 77 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age ≥18.
Histologically confirmed colon and rectum (intraperitoneal) adenocarcinoma.
Pathological classification of primary tumor as pT1-3, pN0 or pN1 (metastases in < 4 regional lymph nodes), without peritoneal tumor deposits, absence of mucinous component >50%, confirmed R0 resection, no limitations for RAS mutations, B-RAF wild type.
No signs of extra hepatic metastatic disease or local recurrence according to CT scan+MRI+PET/CT scans.
Liver metastases not eligible for curative liver resection
Objective response according to RECIST 1.1 to first-line treatment, with sustained response for at least 4 months, OR disease control (complete [CR] or partial response [PR] or standard disease [SD]) during second- line treatment for at least 4 months.
Carcinoembryonic Antigen (CEA) values stable or decreasing during the enrollment prior to liver transplant.
Performance status, ECOG (Eastern Cooperative Oncology Group) 0-2.
Signed informed consent and expected cooperation of the patients for the treatment and follow-up, and national/local regulations.

Exclusion Criteria:

Hereditary CRC syndromes including FAP (Familial adenomatous polyposis) and Lynch syndrome.
Prior extra hepatic metastatic disease or primary tumor local relapse.
Palliative resection of primary CRC tumor.
Disease progression
Other malignancies in the previous 5 years (with exception of in situ cervical carcinoma and basal cell carcinoma; superficial bladder tumors are allowed if curatively treated).
Active intra-venous or alcohol abusers (patients may be eligible if abstention > 6 months is demonstrated)
Active HIV infection
Psychiatric disorders and patient low compliance
Any reason why, in the judgment of the investigators, the patient should not participate (to be formally declared)